Soleus Capital Master Fund, L.P. and related entities filed Amendment No. 5 to a beneficial ownership statement with the SEC on November 9, 2026, disclosing aggregate holdings of 9,425,776 ordinary shares of NovoCure Ltd as of September 30, 2026.

Key Highlights

  • Reporting entity: Soleus Capital Master Fund, L.P. (Cayman Islands) is the direct holder of all reported shares, with Guy Levy named as sole managing member of Soleus Capital Group, LLC and Soleus GP, LLC.
  • Share count: 9,425,776 ordinary shares of NovoCure Ltd (CUSIP G6674U108) are reported as beneficially owned by each reporting person in the filing.
  • Ownership percentage: The 9,425,776 shares represent 8.1% of NovoCure's ordinary shares, calculated against 116,915,959 shares outstanding as of October 23, 2026.
  • Voting and dispositive power: All 9,425,776 shares are held with shared voting power and shared dispositive power; sole voting power and sole dispositive power are each reported as 0.
  • Triggering event date: The filing identifies September 30, 2026 as the date of the event requiring this amendment.
  • Disclaimer of beneficial ownership: Each related entity and Guy Levy individually "disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d)," according to the filing.

Soleus Capital Group's Reported Position in NovoCure Ltd

According to the filing, the shares are held directly by Soleus Capital Master Fund, L.P., a Cayman Islands entity. Soleus Capital, LLC serves as the sole general partner of the Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, and Soleus Capital Management, L.P. acts as investment manager for the Master Fund. Soleus GP, LLC is identified as the sole general partner of Soleus Capital Management, L.P. Guy Levy is listed as the sole managing member of both Soleus Capital Group, LLC and Soleus GP, LLC.

NovoCure Ltd is listed on NASDAQ:NVCR and issues ordinary shares with no par value per share. The company's ordinary share count of 116,915,959 was drawn from the cover of NovoCure's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, filed with the SEC on October 29, 2026, as the filing states. The 8.1% ownership figure reported by Soleus is calculated against that share count. The filing represents the fifth amendment to this beneficial ownership statement, indicating that prior filings on this position have been made by the same reporting persons.

The filing notes that each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy individually disclaims beneficial ownership of the shares held by the Master Fund except to the extent required to determine obligations under Section 13(d) of the Securities Exchange Act of 1934, and specifies that the filing itself "shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose."

What Was Disclosed

The filing disclosed that Soleus Capital Master Fund, L.P. and five related reporting persons each reported shared beneficial ownership of 9,425,776 NovoCure Ltd ordinary shares, equal to 8.1% of the class, as of a triggering event date of September 30, 2026.